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Abstract
Hormone therapy and anti-ErbB2 therapies are prescribed according to the hormone receptor [estrogen receptor α
(ERα)/progesterone receptor] and ErbB2 status of the initial tumor, but it appears that circulating tumor cells (CTCs)
and, consequently, the metastatic cells may have a different receptor status. As an attempt to meet the crucial
need for identification of the subpopulation of patients that will benefit from more individualized therapies, rapidly
evolving therapies should allow a profiling of the tumors and/or of the CTCs. We established a triple fluorescence
staining using eight cell lines to visualize the CTCs (cytokeratin detection) and then to define their individual ERα and
ErbB2 status. Afterward, we used this method for blood samples from 26 metastatic breast cancer patients. We
identified major differences of ERα levels between the cell lines and even within one cell line. For the metastatic
patients, we detected and characterized CTCs in 38.5% of the patients with a total of 92 CTCs. We could demon-
strate that at least 69.6% of the CTCs exhibit an ERα and/or ErbB2 status different from the status of the primary
tumor and that the CTCs from only 30% of the patients had no change of receptor status. Strikingly, heterogeneities
of the status, aggregation, and size clearly appear within the CTCs. The data we generated outline the importance of
a profiling not only of tumors but also of CTCs to establish individualized treatments. CTCs may then appear as new
prognosis and treatment marker for both metastatic and adjuvant breast cancers.
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Introduction
Breast cancer remains the most common cancer and cause of death for
women worldwide [1]. It is a heterogeneous disease and patient outcome
varies significantly according to subtypes based on prognostic features.
Clear molecular differences have been reported between the pri-
mary tumor and the related metastasis [2–5]. Assessment of estrogen
receptor α (ERα) and progesterone receptor (PR) status is routinely
performed by immunohistochemistry of the primary tumor to deter-
mine patient eligibility for adjuvant or palliative hormone treatments
in breast cancer patients. In parallel, patients are selected for ErbB2-
targeted therapies using either immunohistochemistry or gene amplifi-
cation by fluorescence in situ hybridization (FISH) also on the primary
tumor. Nonetheless, it is known that metastatic diseases do not always
share the same characteristics with the primary tumors, with at least
20% of change of tumor phenotype [6]. The progression of the disease
may only be possible if new biologic characteristics are acquired by few
cells. Only those selected cells reach the blood circulation and elicit the
metastatic process [7]. Moreover, those characteristics may be impaired
during the treatment itself. The common change of ERα/PR and of
ErbB2 status between the primary tumor and the metastases can ex-
plain the resistance to hormone therapy and poor outcome of some
of the so-called ERα/PR- or ErbB2-positive patients [3–5,8]. The
change from receptor positivity to triple receptor negativity has been
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confirmed with recurrent disease [4]. Consequently, the hormone re-
ceptor and ErbB2 status of the primary tumor may not be the best
therapy response markers of metastatic cells and reevaluation of metas-
tasis is essential [6]. As blood is an easily available material, new circu-
lating therapy markers shall be identified [9,10].
Circulating tumor cells (CTCs) are defined as tumor cells circulating
in the peripheral blood of patients, issued from either the primary tu-
mors or the metastases. However, the prognostic relevance of CTCs in
the peripheral blood of breast cancer patients is still under investigation.
CTCs detected in breast cancer patients are significantly associated with
a worse outcome, for both localized and metastatic tumors (for reviews,
see [11–16]). Many techniques have been developed in the last 20 years
to detect, isolate, and characterize CTCs in cancer patients and espe-
cially in breast cancer patients [17,18]. The main methods developed
today are individual cytometric analysis using specific monoclonal anti-
bodies against epithelial cells or reverse transcription–polymerase chain
reaction (RT-PCR) to amplify epithelial specific genes. In any case, an
initial enrichment step is proposed, with size filtration or the use of
antibody-coated magnetic beads (e.g., CellSearch System; Veridex,
Raritan, NJ). As suggested [19], the lack of specificity may come not
only from the technique but also from the biology of the tumors them-
selves. The presence of CTCs may not be the only criteria to consider
but also their individual characterization in terms of markers, expected
to be introduced as real-time biopsy to reassess predictive markers over
the progression of the disease [20–26].
Some exciting literature already exists on the evolution of ERα,
PR, and ErbB2 between the breast primary tumors and/or the CTCs
and disseminated tumor cells (DTCs). It was established that breast
cancer primary tumor and DTCs display between 10% and 60% of
concordance for ERα or ErbB2 status using a double immuno-
fluorescence staining [27–30]. Using an RT-PCR approach, the
low concordance rates for ERα, PR, and ErbB2 status was confirmed
between the primary tumors, the CTCs (13% of patients), and the
DTCs (24% of patients) [31]. A high proportion of the CTCs were
ERα/PR-negative despite the presence of ERα/PR-positive primary
tumors. By comparing the two reference techniques that are the Cell-
Search System and the AdnaTest BreastCancer (RT-PCR), significant
rates of metastatic breast cancer patients with ErbB2-negative tumors
shifted to ErbB2-positive CTCs (32% and 49%, respectively) [32].
Altogether, the literature shows that CTC express less often ERα/
PR and more often ErbB2 than the primary tumor cells, and this
may explain some of the resistance to hormone therapy or anti-
ErbB2 treatment. The predictive value of the hormone receptor
and ErbB2 profile of CTCs for both adjuvant and palliative targeted
therapies has to be evaluated further [33,34]. Most reports study
mRNA expression of potential markers in CTCs and DTCs, but it
is of great importance, for ERα and ErbB2, to study the effective
protein expression in CTCs, in the same way as it is performed by
immunohistochemistry for the primary tumors at the time of the
diagnosis. We then developed this approach of individual CTC
characterization for simultaneous ERα and ErbB2 expression, from
breast cancer cell models to a validation with 26 metastatic patients.
Materials and Methods
Cell Culture and Cytospin Preparation
The human adenocarcinoma cell lines MCF-7, T47D, ZR-75-1,
MDA-MB-231, and Ishikawa (Heraklio) 02 ER− (Ishikawa ERneg)
were obtained from the European Collection of Cell Cultures
(ECACC, Salisbury, United Kingdom) and the Cama-1 (HTB-21)
and SK-BR-3 (HTB-30) cell lines from the American Type Culture
Collection (ATCC, Rockville, MD). HCC 3153 cell line was kindly
provided by Adi F. Gazdar (Hamon Center for Therapeutic Oncology
Research and Department of Pathology, University of Texas South-
western Medical Center at Dallas, Dallas, TX). Cryopreservation of
cell cultures ranged from passages 1 to 10. Cells were used during up
to 20 passages. Cells were grown routinely in Dulbecco’s modified
Eagle’s medium (Biochrom, Berlin, Germany), supplemented with
10% FBS (PAA, Pasching, Austria).
For cytospin preparation, trypsinized cells were centrifuged (700g,
10 minutes, 4°C) and resuspended in phosphate-buffered saline
(PBS; Biochrom). Then, 1 million cells were spread on each cytospin
and centrifuged (45g, 5 minutes, room temperature). Cytospins were
allowed to dry overnight at room temperature and then stored at
−80°C. They were prepared with either 1 million adenocarcinoma
cells or mixed with peripheral blood cells (PBCs) from healthy vol-
unteer donors as indicated in the legends.
Fluorescence Labeling of Cytokeratin (CK) with Parallel
4′-6-diamidino-2-phenylindole (DAPI) Analysis
Cytospins were defrozen and immediately fixed in 3.7% neutral buff-
ered formalin in PBS (Fischar, Saarbrücken, Germany) for 15 minutes
at room temperature and permeabilized in cold (−20°C) methanol
(Sigma-Aldrich, Steinheim, Germany) for 2 minutes. After washing
in PBS, Ultra V Blocking medium (Thermo Scientific, Fremont,
CA) was used. This blocking step and all the following steps were per-
formed in a humidified chamber at room temperature. All antibodies
were diluted in Dako Antibody Diluent with Background Reducing
Components (Dako, Carpinteria, CA).
Cells were incubated for 45 minutes with a mouse anti-human cytoker-
atin (A45 B/B3;Micromet,Munich, Germany). It is a purifiedmonoclonal
pan-cytokeratin antibody, which specifically detects the epithelial cytoskel-
eton components CK8, CK18 and CK19. After washing, cells were incu-
bated for 30 minutes with a goat anti-mouse IgG labeled with DyLight488
(Jackson ImmunoResearch, West Grove, PA) and washed in PBS.
After drying (30 minutes, at room temperature), the slides were
mounted with Vectashield Mounting Medium with DAPI (Vector
Laboratories, Burlingame, CA) before manual analysis with a com-
puterized fluorescence microscope Axioskop (Carl Zeiss Micro Imaging
GmbH, Göttingen, Germany) with ×10 magnification.
Triple Fluorescence Labeling of CK, ERα, and ErbB2 with
Parallel Phase Analysis
Starting from the fluorescence staining procedure of CK and ERα
in DTCs [28], various parameters were optimized, as described in the
Supplementary Materials and Methods. Criteria for CK positivity
were the ring-like appearance (cytoplasm staining in periphery) and
we considered ERα positivity low, moderate, or high, always for specific
staining of the nucleus with a low background, a strong nuclear, and no
cytoplasmic or peripheral staining. Criteria for ErbB2 overexpression
were a completely positive membrane staining (moderate or strong).
We followed the criteria already described for identification of
ErbB2-positive DTCs by immunofluorescence [27] and the consensus
recommendations for standardized tumor cell detection [35].
Cytospins were defrozen, immediately fixed, permeabilized, and
blocked as described above.
Cells were then first incubated for 45 minutes with a rabbit mono-
clonal anti-human ERα antibody (clone sp-1; Lab Vision, Fremont,
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CA), washed, incubated for 30 minutes with a goat anti-rabbit IgG-
Fab fragment labeled with Cy3 (Jackson ImmunoResearch), and
washed in PBS.
Cells were then incubated for 45 minutes with a rabbit polyclonal
anti-human ErbB2 antibody (A0485; Dako, Glostrup, Denmark)
and a mouse anti-human cytokeratin antibody (A45 B/B3; Micro-
met), washed, incubated for 30 minutes with a goat anti-rabbit IgG
labeled with Coumarin-AMCA (Jackson ImmunoResearch) and a
goat anti-mouse IgG labeled with DyLight488 (Jackson Immuno-
Research), and washed in PBS.
After drying (30 minutes, at room temperature), the slides were
mounted with Kaiser’s glycerol gelatin (Merck, Darmstadt, Germany)
before manual analysis with a computerized fluorescence microscope
Axioskop (Carl Zeiss Micro Imaging GmbH) for phase and fluores-
cence, with ×10 and ×40 magnifications. An AxioCam MR camera
and an AxioVision software were used to capture, analyze, and save
high-resolution images for the three fluorescence channels, considered
independently or in combination (Carl Zeiss Microscopy, Göttingen,
Germany). Definite threshold values of exposure time for ERα, ErbB2,
and CK fluorochromes were determined, on the basis of the analysis
of the eight cancer cell lines, and systematically used for patient analysis
described below.
Western Blot Analysis
Cells were lysed with a RIPA buffer containing protease inhibitor
cocktail (Sigma-Aldrich, Deisenhofen, Germany). Afterward, 10 μg of
protein was separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and then blotted on a polyvinylidene difluoride (PVDF)
membrane (Roth, Karlsruhe, Germany). A rabbit monoclonal anti-
human ERα antibody was used (clone sp-1; Lab Vision), without β-actin
normalization, whose expression was too heterogeneous between the cell
lines. A secondary biotinylated anti-mouse IgG antibody was used and
then chemiluminescence detection was performed (Vectastain ABC-
AmP for Western Blotting Rabbit-IgG Kit; Vector Laboratories).
ERα Detection by Immunocytochemistry Followed
by a Colorimetric Detection
Cytospins were defrozen, fixed, and permeabilized as described above,
before performing a blocking step using normal serum (Vectastain Elite
ABC Kit; Vector Laboratories). Afterward, cytospins were incubated
either with a primary monoclonal mouse antibody against ERα (clone
1D5; Dako, Glostrup, Denmark) or with a mouse IgG antibody as a
negative control (Dako, Glostrup, Denmark). After incubation with a
biotinylated secondary anti-mouse IgG antibody and the avidin-biotin-
peroxidase complex (same Vectastain Elite ABC Kit), visualization was
performed with substrate and chromogen 3-amino-9-ethylcarbazole
(Dako, Carpinteria, CA). The slides were immediately mounted with
Aquatex (Merck) before manual analysis with a Diaplan light micro-
scope (Leitz, Wetzlar, Germany) with ×40 magnification.
Patient Cohort
This analysis was performed at the Department of Obstetrics and
Gynecology, Ludwig Maximilian University (Munich, Germany).
Twenty-eight metastatic breast cancer patients were recruited from
Table 1. Metastatic Breast Cancer Patient Characteristics and CTC Presence.




TNM Grade ERα PR ErbB2
M1CTC 52 pT2, pN2, M0 G2 Pos Pos Neg 5 and 10 10
M2CTC 57 cT4, N3, M1 G3 Neg Neg Pos 0 1
M3 65 pT1c, pN2, M0 G2 Pos Neg Neg 7 9
M4 65 cT3, pNx, pM1 G3 Neg Neg Pos 0 and 1 1
M6CTC 45 ypTis, pN1, M0 G3 Neg Neg Pos 2 3
M7CTC 71 pT2, pN1, M0 ND Pos Neg Neg§ 7 12
M8 49 pT1b, pN0, M0 G2 Pos Pos Neg 8 12
M9CTC 59 pT1c, pN0, M0 G2 Pos Pos Neg 8 12
M10CTC 65 Left: pT2, pN0, M0 G2 Pos Neg Pos 5 and 6 6
Right: pT1c, pNx, M0 G2 Pos Neg Pos
M11 62 ypT2, pN3a, M0 G3 Pos Pos Neg 2 and 3 5
M12 59 ypT2, pN2, M0 G3 Neg Neg Pos 3 7
M13 73 pT2, pN1, M0 G2 Pos Pos Neg 2 and 6 7
M14CTC 58 ypT4, pN0, M0 G2 Neg Neg Neg 1 2
M15 78 cT3, cN1, cM1 G2 Pos Pos Pos 0 1
M16CTC 65 pT1c, pN0, M0 ND Pos Pos Neg 10 and 12 12
M17 60 pT1c, pN0, M0 ND Pos Pos Pos 6 9
M18 67 pT4b, pN1, pM1 G2 Pos Pos Neg 0 0
M19 65 pT2, N0, M0 G2 Neg Neg Pos 0 0
M20 57 pT3, pN3, M1 ND Pos Neg Neg 0 and 1 1
M21 58 pT1c, pN3, M0 ND Pos Pos Pos 10 10
M22 49 pT2, pN0, M0 G3 Neg Neg Neg 4 4
M23CTC 57 pT1c, pN0, M0 ND Neg Pos Neg 12 and 13 15
M25CTC 69 Left: pT1c, pN0, M0 G1 Pos Pos Neg 5 6
Right: pT2, pN0, M0 G2 Neg Neg Neg
M26 42 ypT0, pN1a, M0 G2 Pos Pos Neg 1 1
M27 56 Left: pT2, pN1, M1 G2 Pos Pos Neg 0 and 2 3
Right: pTis, pNx, M1 ND ND ND ND
M28 75 ypT3, pN1a, M0 G2 Pos Pos Neg 9 9
CTC, CTC-positive patients.
*At time of CTC analysis.
†Time between primary diagnosis and metastasis (years).
‡Time between primary diagnosis and CTC analysis (years).
§No information for the primary tumor but ErbB2-negative recurrence 10 years later (ERα-positive and PR-negative as the primary tumor).
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May 2010 to May 2012, with two exclusions [patient M5 with a
cancer of unknown primary origin (CUP) syndrome and patient
M24 with insufficient blood sample]. Table 1 describes the character-
istics of the 26 selected patients and of their primary tumors. Written
consent forms were collected from the patients using protocols ap-
proved by the Institutional Ethics Committee (Approval No. 148-12;
Ethikkommission bei der Ludwig-Maximilians Universität, Munich,
Germany). The phenotype of the primary tumor was routinely assessed
at the time of diagnosis by immunohistochemical staining and eventu-
ally by FISH (for most ErbB2++ patients) in the relevant Department of
Pathology and collected from the patient files. ERα status was classified
by evaluation of the percentage of tumor-stained cells and staining in-
tensity, allowing assessment of an immunoreactive score (IRS = % score ×
intensity score). ErbB2-negative assessment includes 0 or + stainings
and ++ staining with FISH-negative amplification, and ErbB2-positive
assessments include ++ with FISH amplification or +++ staining. ERα
and ErbB2 status were indicated in the tables, if available. Because the
ErbB2 status of the primary tumor of patient M7 was not determined
Figure 1. Labeling of CK, ERα, and ErbB2 in MCF-7 and SK-BR-3 cells. (A) SK-BR-3 cells (100 to 500,000) were diluted with PBCs to reach
1 million cells per cytospin. The fluorescence labeling of CK was performed together with a DAPI nuclear staining. Original magnifica-
tion, ×10. (B) The triple fluorescence labeling of CK, ERα, and ErbB2 was performed on 1 million MCF-7 cells (ERα-positive and ErbB2-
negative) or 1 million SK-BR-3 cells (ERα-negative and ErbB2-positive). Phase analysis was performed in parallel. Original magnification,
×40. Scale bar, 100 μm in A and 10 μm in B.
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in 1999, at the time of diagnosis, we considered the ErbB2-negative
status of the local recurrence assessed in 2009, with ERα positivity
and PR negativity recorded for the primary tumor.
Blood Sampling, Ficoll, and Cytospin Preparation
Fifteen milliliters of blood from each patient was collected in
EDTA tubes. The blood was processed by a modified Ficoll protocol,
with density gradient separation over Ficoll [36]; the cells were counted
and centrifuged (700g, 10 minutes at 4°C), and then 1 million cells
were spread out on cytospins, processed as described above.
Patient Analysis by Triple Fluorescence
Triple fluorescence labeling of CK, ERα, and ErbB2, with parallel
phase analysis, was performed on the cytospins prepared from patient
blood, as described above. Preparation of the ERα-positive breast
cancer cell line MCF-7 mixed with PBCs from patients served as
positive control for ERα and CK staining and as a negative control
for ErbB2 staining, whereas preparation of the ERα-negative breast
cancer cell line SK-BR-3 mixed with PBCs was used as positive con-
trol slides for ErbB2 and CK staining and negative control slides for
ERα staining. In each batch of patient samples, one MCF-7 and one
SK-BR-3 control slide were systematically performed and controlled.
For each patient, two cytospins were analyzed (2 million cells per pa-
tient) and each slide was evaluated by two independent investigators
and three in doubtful cases (C.B., S.D.S., and U.J.). For three patients
(n = 11.5%), the evaluation of the two observers differed for either the
CTC detection or ERα positivity. These cases were reevaluated by the
three observers together. After the reevaluation, the observers came to
the same result. The concordance before the reevaluation was 88.5%.
The analysis was always performed within 48 hours after the labeling
procedure. Each observed CTC was recorded with at least one picture
for each channel of analysis.
Statistical Analysis
A Freeman-Halton extension of the Fisher exact probability test
was used to evaluate the relationship between the receptor status of
Figure 2. Triple fluorescence labeling of CK, ERα, and ErbB2 in eight cell lines. The triple fluorescence labeling of CK, ERα, and ErbB2 was
performed on 1 million cells that were mixes of cells of one human carcinoma cell line and PBCs (1:4). Phase analysis was performed in
parallel. Original magnification, ×40. Scale bar, 10 μm.
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the 26 patients with a primary tumor and the 10 CTC-positive pa-
tients. P < .05 was considered statistically significant.
Results
Fluorescence Labeling of CK, ERα, and ErbB2 in Human
Carcinoma Cell Lines
To mimic the physiological situation of very few CTCs to identify
among many PBCs, we first used MCF-7 and SK-BR-3 cells as models
for, respectively, ERα-positive and ErbB2-positive breast cancer cells
and mixed them with PBCs. By using various definite numbers of
SK-BR-3 cells with PBCs, we stained the CK with a pan-cytokeratin
that recognizes epithelial cytoskeleton components and counterstained
the nucleus with DAPI (Figure 1A). Using the DAPI channel (left), we
could visualize the similar number of total cells in the three preparations
and the decreasing numbers of epithelial cells labeled in green by the
anti-CK antibody (right). By the highest dilution of one SK-BR-3 in
104 PBCs, we could easily spot, at a magnification of ×10, the CK-
positive cells among the numerous PBCs.
We then followed the triple fluorescence protocol for both MCF-7
and SK-BR-3 cells (Figure 1B). The ×40 magnification allowed here
to visualize, besides the phase images, the ring-like appearance of CK
labeling in both cell lines, the nuclear staining of ERα in MCF-7
cells, and the membrane labeling of ErbB2 in SK-BR-3, confirmed
by the superposition of CK with either ERα or ErbB2.
As shown in Figure 2, we performed this protocol on seven breast
human cancer cell lines and one endometrial (Ishikawa ERneg) human
cancer cell line to analyze the differences in ERα expression and ErbB2
overexpression, with four ERα-positive cell lines (MCF-7, T47D,
Cama-1, and ZR-75-1) and four ERα-negative cell lines (SK-BR-3,
Ishikawa ERneg, HCC 3153, and MDA-MB-231). We obtained clear
results for each cell line with systematic CK labeling, specific character-
ization of the different ERα levels (no ERα: −, low ERα: +, moderate
ERα: ++, and high ERα: +++), and overexpression or none for ErbB2.
As expected, SK-BR-3 cell line was the only one to overexpress ErbB2.
Regarding ERα, the four ERα-negative cell lines were confirmed and it
clearly appeared that ERα levels are different not only in between the
different cell lines but also even within one cell line, with cells express-
ing no, low, moderate, or high levels of ERα. The following grading
was obtained for ERα in the so-called “ERα-positive cells”: MCF-7:
ERα+ to ERα+++; T47D: ERα++; Cama-1: ERα− to ERα++; and
ZR-75-1: ERα− to ERα+++. Especially in Cama-1 and ZR-75-1, some
cells express such low levels of ERα that we technically consider them
as ERα−.
Figure 3. ERα expression analysis in MCF-7 and other cell lines. (A) ERα expression of cell lysates from the eight human carcinoma cell
lines was analyzed by Western blot analysis. Representative of three independent experiments. (B) ERα expression of cytospins from
the eight human carcinoma cell lines was analyzed by immunocytochemistry followed by colorimetric detection. Representative of three
independent experiments. (C) Comparison of the intensity of ERα expression of cytospins of MCF-7 cells analyzed by either the fluores-
cence protocol (left) or immunocytochemistry followed by colorimetric detection (right). Scale bar, 10 μm.
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Analysis of the Intensity of ERα Expression in MCF-7
and Other Cell Lines
To confirm these heterogeneities, we performed first a Western
blot analysis and observed again significant differences of ERα ex-
pression within the ERα-positive cells (Figure 3A), the ZR-75-1 cells
exhibiting a particularly low total expression. In Figure 3B, we analyzed
ERα expression in the eight cell lines, using immunocytochemistry
analysis followed by a colorimetric detection typically used for ERα
status determination in the primary tumors. The results are in complete
agreement with the fluorescence results from Figure 2, clearly showing
the various levels of ERα expression of the ERα-positive cell lines. In
Figure 3C , the example of MCF-7 cells stained with either the triple
fluorescence detection (left) or the colorimetric detection (right) shows
the very similar ability of both techniques to distinguish low, moderate,
and high ERα-expressing cells.
ERα and ErbB2 Status Determination in CTCs from Patients
Twenty-six patients were included in the study with clinical data
shown in Table 1 and an average age of 60.7 years (42–78). Two
patients had bilateral breast cancers: patient M10 (two ERα- and
ErbB2-positive tumors) and patient M25 (one ERα-positive and
ErbB2-negative tumor on the left breast and one ERα- and ErbB2-
negative tumor on the right breast). Their tumors have then been con-
sidered as two independent primary tumors in the following statistics.
Nineteen (67.8%) primary tumors were ERα-positive, 10 (35.7%)
were ErbB2-positive (with 5 patients both ERα- and ErbB2-positive),
and 3 (10.7%) were triple negative. The analysis we performed dem-
onstrated the presence of CTCs in 10 patients, i.e., 38.5%. Although
the percentage of patients with an ERα-positive tumor is lower for the
CTC-positive population compared to the total population, there is no
statistically difference between those two populations [status of the pri-
mary tumors of the 10 CTC-positive patients: 7 (58.3%) ERα-positive,
4 (33.3%) ErbB2-positive (with 1 patient both ERα- and ErbB2-
positive), and 2 (16.7%) triple negative].
The analysis of the 92 CTCs visualized for the 10 CTC-positive
patients is presented in Table 2, with numbers ranging from 1 to
43 CTCs (per 2 million PBCs for each patient). Six patients had
more than one CTC visualized and three patients had even more
than 10 CTCs. Only 28 CTCs (30.4%) had identical ERα and
ErbB2 status to the primary tumor, whereas the 69.6% remaining
CTCs had a different status. Forty-four (47.8%) were characterized
by a discrepant status of both ERα and ErbB2, 58 (63%) by the
“loss” of ERα, and 48 (52.2%) by the “gain” of ErbB2. Only two
CTCs (2.2%) from patient M6 exhibited a “gain” of ERα, who is a
patient treated by trastuzumab and no hormone therapy.
Table 3 summarizes the results regarding the percentage of pa-
tients who exhibit or not a difference between the primary tumor
and CTC, in either ERα (left) or ErbB2 (right). Sixty percent had
a change in ERα and 30% in ErbB2 expression. We analyzed that
70% had a change in one or both receptors.
In Figure 4, the images of few representative CTCs from the
43 CTCs of patient M1 (upper) are shown. It was remarkable that
this patient, classified 10 years earlier as having an ERα-positive and
ErbB2-negative tumor, had CTCs expressing the four possible
Table 2. Characteristics of the Primary Tumors and 92 CTCs of the 10 Patients with CTCs.
Patient Primary Tumor Status Therapy* CTC Status Change in CTC Status Compared
to the Primary Tumor Status
ERα ErbB2 Amount ERα ErbB2
Status %† IRS Status Intensity
M1 Pos 80% I2 (no IRS) Neg ++ No FISH amplification AI 2 Pos Pos ErbB2 positivity
1 Pos Neg None
39 Neg Pos Opposite status
1 Neg Neg ERα negativity
M2 Neg <10% 1/12 Pos +++ Tz 1 Neg Pos None
M6 Neg 0% 0/12 Pos +++ Tz 2 Pos Pos ERα positivity
M7 Pos 40% I2 (no IRS) Neg‡ ND Tam, AI, Ful 2 Pos Neg None
5 Neg Pos Opposite status
8 Neg Neg ERα negativity
M9 Pos 50% 1 (no IRS) Neg 0 Tam, AI 1 Neg Neg ERα negativity
M10 Left: Pos ND 12/12 Pos +++ Tam, AI, Tz 1 Neg Pos ERα negativity
Right: Pos 81% 12/12 Pos +++
M14 Neg 0% 0/12 Neg ++ No FISH amplification − 2 Neg Pos ErbB2 positivity
M16 Pos 70% I2 (no IRS) Neg ND AI, Tam 3 Neg Neg ERα negativity
M23 Neg <10% ND Neg ND Tam, AI, Ful 1 Neg Neg None
M25 Left: Pos >80% 8/12 Neg + Tam, AI 23 Neg Neg ERα negativity
Right: Neg 0% 0/12 Neg 0 None
*AI, aromatase inhibitor; Tam, tamoxifen; Ful, fulvestrant; Tz, trastuzumab.
†Percentage of ER-positive cells was assessed by immunohistochemistry at time of diagnosis.
‡No information for the primary tumor but ErbB2-negative recurrence 10 years later (ERα-positive and PR-negative as the primary tumor).
Table 3. Correlations of the Receptor Status between the Primary Tumors and the CTCs.
CTCs CTCs
All ERα-pos All ERα-neg ERα-pos and ERα-neg All ErbB2-pos All ErbB2-neg ErbB2-pos and ErbB2-neg
Primary tumor* ERα-pos 0% 30% 20% Primary tumor* ErbB2-pos 30% 0% 0%
Primary tumor* ERα-neg 10% 40% 0% Primary tumor* ErbB2-neg 10% 40% 20%
*Percentages are calculated according to n = 10, number of patients, considering only the ERα- and ErbB2-negative tumors of patient M25.
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receptor profiling (ERα- and ErbB2-positive in A, ERα-positive and
ErbB2-negative in B, ERα-negative and ErbB2-positive in C, and
ERα- and ErbB2-negative in D). As for some other patient’s CTCs,
clusters of CTCs appeared in C, all having the same profiling within
one cluster in our study. We noticed that ErbB2 overexpression was
especially high for the 39 ERα-negative and ErbB2-positive CTCs
of this patient, in comparison to the SK-BR-3 cells and to the 13 other
ErbB2-positive CTCs we analyzed. This patient is an example of
ErbB2-positive CTC related to an ErbB2-negative primary tumor,
but it is important to consider the ErbB2 negativity criteria for primary
tumors. This was classified as ErbB2-negative with an ErbB2 expres-
sion of ++, because of the absence of amplification by FISH analysis
(Table 2). Consequently, the selection of the overexpressing ErbB2
CTCs may have been natural over the time and/or facilitated by the
therapy. This may not be a rare event as in our study patient M14
was another example (ErbB2-positive CTCs related to an ErbB2-
negative primary tumor, with ++ expression but no amplification).
Two representative CTCs of breast cancer patients are shown in
Figure 4 (lower) with patient M7. This patient exhibits a size hetero-
geneity within her 15 CTCs, as already recorded to some extent,
within the CTCs from different patients. Nonetheless, the difference
(from 6- to 10-μm diameter) was the highest for this patient and in-
dependent of the hormone status.
Discussion
The literature clearly shows that reliance on the phenotype of the
primary tumor to establish a therapeutic protocol can be misleading,
as ERα, PR, and ErbB2 status are often differentially expressed in
CTCs compared to the primary tumor [37]. To validate further these
differences, efficient techniques that allow not only to assess the
CTC number but also the CTC profiling, especially regarding their
individual receptor status, are necessary. Moreover, CTC analyses
may have to focus on the determination of the actual protein expres-
sion of the markers and not only of their transcript levels, as correla-
tions between mRNA and protein expressions have not been clearly
established so far.
We used various human carcinoma cell lines and developed a
simple and efficient technique of CTC receptor analysis using triple
fluorescence. By mixing cancer cells with PBCs, we could mimic the
extreme dilutions of CTCs in blood and always performed internal
negative controls with the absence of staining for PBCs. It has been
suggested that PBC fractions from healthy donors, especially mono-
cytes, may express very low levels of mRNA of CK (18/19) and ErbB2
[38]. This has to be distinguished from the clear overexpression of CK
we visualized for both human carcinoma cells and then all CTCs from
patients, confirmed by morphologic criteria for malignant cells. For
ErbB2 positivity assessment, we considered a significant level of
Figure 4. ERα and ErbB2 status determination in CTCs from patients M1 and M7. The triple fluorescence labeling of CK, ERα, and ErbB2
was performed on 1 million PBCs from patients. Phase analysis was performed in parallel. CTCs from patients M1 and M7 are shown
with four hormone status observed for patient M1 (a–d) and size heterogeneity for CTCs of patient M7 (e and f). Original magnification,
×40. Scale bar, 10 μm.
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ErbB2 expression compared to SK-BR-3 overexpression. Besides, in-
dividual assessments of either ERα or ErbB2 were already successfully
performed in DTCs by similar protocols [27].
A first evidence that appeared from ERα fluorescence labeling was
the heterogeneity of expression between the so-called “ER-positive”
cell lines. This heterogeneity, already reported [39], was confirmed in
our study by Western blot analysis and colorimetric detection. We
used the immunocytochemistry staining followed by a colorimetric
detection to mimic the immunohistochemistry reference technique
used in the anatomopathologic departments for the analysis of
ERα expression in the primary tumors, recurrences, and/or metas-
tasis. Because the distinction of low, moderate, and high intensities
of ERα expression is the basis of tumor grading, it was a priority that
the triple fluorescence analysis could reach the same standards. Definite
threshold values of exposure time for ERα, ErbB2, and CK fluoro-
chromes were absolutely required for this evaluation. We demonstrated
the very similar abilities of both techniques to distinguish the cells with
the three levels of expression of ERα from technically ERα-negative
cells. It is noteworthy that some of the expected ERα-positive cells ex-
press such low levels of ERα that they are considered as ERα-negative
by both techniques. As an example, we evidenced for the Cama-1 and
ZR-75-1 cell lines a significant percentage of cells with extremely low
levels of ERα that we technically considered as ERα-negative. Besides at
least 99% of MCF-7 cells express ERα but with strong differences of
intensity. This heterogeneity relies partly on the cell cycle–related var-
iations of ERα expression [40], as observed in the tumors of the pa-
tients. Such a heterogeneity of the cell cycle protein is proposed to
drive resistance to the treatments and/or metastasis [40,41]. Even with
more than 90% of ERα positivity in a tumor, only one cell that is ERα-
negative may resist to any hormone therapy and promote extravasation,
CTC appearance, and metastatic process. For ErbB2 overexpression,
the situation is similar with at least 80% of cells that are proved to carry
ErbB2 amplification, being aware that even one ErbB2-negative cell
may drive resistance to trastuzumab treatment.
We performed the triple fluorescence analysis on blood samples
collected from a consecutive cohort of 26 metastatic breast cancer
patients. The morphology and fluorescence stainings (irregular cyto-
plasmic staining for cytokeratin) were representative of CTCs from
breast cancer patients and we observed CTCs in 38.5% of patients.
This rate is in accordance with the results already presented for meta-
static patients. Higher rates can be expected according to the stage and
detection technique and being aware that the expression of cyto-
keratins evolves during the metastatic process of breast cancers
[32,42]. Nonetheless, CTC positivity seems to be restricted to two
thirds of the metastatic patients and patients without detectable
CTCs comprise a heterogeneous group with substantially different
prognosis [43].
Regarding ERα and ErbB2 status, we obtained 30.4% of con-
cordance rate between the primary tumor and the CTCs, with, conse-
quently, 69.6% of the 92 CTCs that exhibit a receptor status different
from the primary tumor status. It is noteworthy that for patient M25
who had bilateral tumors with one triple negative (grade 2) and one
ERα-positive and ErbB2-negative (grade 1), 23 CTCs were analyzed
that were all ERα- and ErbB2-negative. Consequently, we hypoth-
esized that the CTCs had their origin in the more aggressive triple
negative tumor with no change of the CTC receptor status in this case.
Nonetheless, at least some of the 23 CTCs may also derive from the
grade 1 primary tumor with a selection/evolution of ERα-negative cells.
If so, the concordance rate between the primary tumor and the CTCs
could be even lower (5.4%), and up to 94.6% of CTCs could have a
different status. The concordance rates between the primary tumor and
CTCs are quite low in any case and in complete agreement with the
literature [31,44].
Considering these discrepancies, the relevance of the hormone or
ErbB2-targeted therapies should be defined according to the CTC sta-
tus. For this, more clinical trials should be designed to correlate the
CTC status with the therapy efficacies. In our hands, at least 63% of
the CTCs are characterized by the “loss” of ERα, compared to the sta-
tus of the primary tumor, with 92% of ERα-negative CTCs. Besides,
100% of the patients with ERα-positive primary tumor had ERα-
negative CTCs and 90% of patients had at least one ERα-negative
CTC. This high percentage of ERα-negative CTCs can also derive
from the few ERα-negative cells present in the so-called ERα-positive
primary tumors.
For ErbB2 expression, 54.3% of the 92 CTCs are characterized by
a “gain” of ErbB2 compared to the primary tumor status, with a total
of 56.5% of ErbB2-positive CTCs. Besides, none of the patients
with ErbB2-positive primary tumors had ErbB2-negative CTCs
and 30% of the patients with ErbB2-negative tumors had ErbB2-
positive CTCs.
A major issue to consider is the heterogeneity of ERα or ErbB2
expression in CTCs of each patient. It was already described in DTCs
[27,29,31] and in CTCs [32], with the requirement of a cutoff level
of CTC number with ErbB2 positivity to define the candidate for
ErbB2-targeted therapy, for either adjuvant or metastatic patients. In
our study, heterogeneity of both ERα and ErbB2 expression in CTC
was observed for two patients (20%). The analysis of a higher volume of
blood and total number of PBCs may increase this percentage.
It is suggested that CTCs mostly derive from triple negative tumors,
with percentages of triple negativity (assessed at the transcript level) rais-
ing from 15% for primary tumors of breast cancer patients to 50% for
their CTCs [31]. The data we generated at the protein level confirm
this hypothesis: three patients of our cohort (11.5%) were diagnosed
with a triple negative primary tumor and two of them had CTCs.
Among the 10 patients with presence of CTCs, 6 (60%) had at least
1 ERα- and ErbB2-negative CTC.
Altogether, 70% of the patients had a different receptor status be-
tween the primary tumor and CTCs (with less ERα positivity and
more ErbB2 positivity in CTCs) and the 30% remaining exhibit
mainly ERα- and ErbB2-negative tumors and CTCs. An interesting
approach used a fiber optic array scanning technology to detect ErbB2
and ERα expression in CTCs of 18 metastatic breast cancer patients
[44]. The recorded actionable discordance rates, 40% and 23%, re-
spectively, for ERα and ErbB2, were similar to the one we obtained
(60% and 30%, respectively). However, in contrast to the reported
60% of ERα-negative tumors that led to ERα-expressing CTCs, we
identified only 10% (one patient, i.e., 2.2% of the CTCs analyzed).
Besides this discrepancy, the results already published and ours are
converging, considering the still limited number of cases analyzed
in most studies.
The physiopathologic significance of the CTC clusters, we and
others observed, and the size heterogeneity of CTCs are crucial
points that may lead to further analyses [17]. The former issue is
supported by results published regarding the presence of clusters of
4 to 12 CTCs in the circulation of metastatic prostate or lung cancer
patients (3 of 19 patients) [45] or of DTC clusters in breast cancer
patients [28,31]. In that latter studies, clear heterogeneity of either
ERα or ErbB2 expression was demonstrated among DTCs associated
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in one cluster, whereas the CTC clusters observed in our study for four
patients always exhibited the same receptor profiling within one clus-
ter. We already outlined the remarkable overexpression of ErbB2 ob-
served in 39 of 43 CTCs from patient M1, who had an ERα-positive
and ErbB2-negative primary tumor (++ ErbB2 staining but no ampli-
fication by FISH) 10 years earlier and, consequently, an anti-aromatase
treatment. The efficacy of this treatment may have driven a major de-
crease of the proportion of ERα-positive/ErbB2-negative CTCs and
the apparition of ErbB2-positive CTCs by selective pressure.
Regarding the CTC diameter ranging from 6 to 10 μm, the physio-
pathologic significance of this heterogeneity has to be further explored.
We excluded the hypothesis of non-nucleated microparticles that are
defined by a size ranging between 0.1 and 1 μm [46]. Besides, the tech-
nical issue of CTC enrichment techniques has to be considered when
the techniques rely on a size filtration of CTCs from PBCs [47].
The number of total CTCs of breast cancer patients should then be
accompanied by the assessment of their expression of most relevant
receptor, proliferation, and stem cell markers. A recent study performed
with prostate cancer patients nicely demonstrated the relevance of the
proliferation index of the CTCs [48], extending the profiling range of
CTCs to explore. Besides, it is suggested that CTCs may be naturally
enriched in cancer stem cells [42], supporting the invasive ability of
the primary tumors [49]. These are valuable hypothesis to be con-
sidered and evaluated in the near future, both for palliative and
adjuvant therapies.
In future, clinical studies should not only answer questions about
the therapeutic efficacy of certain therapy regimes but should also
enhance the understanding of tumor biology. The hormone receptor
status of CTCs is a very challenging issue if it allows to adjust the
choice of anti-hormone and anti-ErbB2 therapies for each patient.
We need to outline that the technique we propose is simple to adapt
as a routine protocol in any laboratory equipped with a fluorescence
microscope. We generated data that demonstrate a discordance of
either ERα, ErbB2, or both in 70% of the metastatic patients. CTCs
may then appear as new prognosis and treatment marker for meta-
static and adjuvant breast cancers.
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Supplementary Materials and Methods
Optimization of the Triple Fluorescence Labeling of CK, ERα,
and ErbB2
For establishing the labeling procedure described in the Materials
and Methods section, MCF-7 and SK-BR-3 breast cancer cell lines
were mixed with PBCs. Cell fixation and permeabilization were first
assessed (e.g., acetone, ethanol, methanol, formalin, or digitonin at
different temperatures, duration, and dilutions) and the following
protocol was selected: fixation in 3.7% neutral buffered formalin
in PBS for 15 minutes at room temperature and permeabilization
in cold (−20°C) methanol for 2 minutes.
We then tested primary antibodies against ERα, a monoclonal
mouse antibody (clone 1D5; Dako, Glostrup, Denmark) and a
monoclonal rabbit antibody (clone sp-1; Lab Vision) and against
ErbB2, a polyclonal chicken antibody (GeneTex, Irvine, CA), and
a polyclonal rabbit (A0485; Dako, Glostrup, Denmark). In parallel,
we tested different antibody dilutions (from 1:25 to 1:1000) with
PBS or Dako Antibody Diluent with Background Reducing Compo-
nents (Dako, Carpinteria, CA). Incubation times for primary and
secondary antibodies varied from 15 to 45 minutes. Because a pro-
cedure using primary antibodies from three species was not efficient
in our hands, we selected a two-step protocol by using, as secondary
antibodies, a goat anti-rabbit IgG-Fab fragment before a goat anti-
rabbit IgG [1].
Once the labeling procedure was set, we checked that cytospins
frozen for at least 2 years could be used with no alteration of the
staining and that, once stained, fluorescence of cytospins stored at
+4°C could be visualized, with no significant loss of fluorescence,
during at least 2 months (data not shown). Analyses were nonetheless
always performed within 48 hours after the labeling.
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